AAAAAA

   
Results: 1-10 |
Results: 10
THE EFFECT OF TOLCAPONE ON LEVODOPA PHARMACOKINETICS IS INDEPENDENT OF LEVODOPA CARBIDOPA FORMULATION/
Authors: JORGA K FOTTELER B SEDEK G NIELSEN T AITKEN J
Citation: K. Jorga et al., THE EFFECT OF TOLCAPONE ON LEVODOPA PHARMACOKINETICS IS INDEPENDENT OF LEVODOPA CARBIDOPA FORMULATION/, Journal of neurology, 245(4), 1998, pp. 223-230
PHARMACOKINETICS AND PHARMACODYNAMICS AFTER ORAL AND INTRAVENOUS ADMINISTRATION OF TOLCAPONE, A NOVEL ADJUNCT TO PARKINSONS-DISEASE THERAPY
Authors: JORGA KM FOTTELER B HEIZMANN P ZURCHER G
Citation: Km. Jorga et al., PHARMACOKINETICS AND PHARMACODYNAMICS AFTER ORAL AND INTRAVENOUS ADMINISTRATION OF TOLCAPONE, A NOVEL ADJUNCT TO PARKINSONS-DISEASE THERAPY, European Journal of Clinical Pharmacology, 54(5), 1998, pp. 443-447
EFFECT OF LIVER IMPAIRMENT ON THE PHARMACOKINETICS OF TOLCAPONE AND ITS METABOLITES
Authors: JORGA KM KROODSMA JM FOTTELER B HEIZMANN P MEYER J RASCH MC VANHATTUM J
Citation: Km. Jorga et al., EFFECT OF LIVER IMPAIRMENT ON THE PHARMACOKINETICS OF TOLCAPONE AND ITS METABOLITES, Clinical pharmacology and therapeutics, 63(6), 1998, pp. 646-654
EFFECT OF THE COMT INHIBITOR TOLCAPONE ON THE HEMODYNAMIC-EFFECTS ANDTOLERABILITY OF THE COMBINATION TREATMENT WITH LEVODOPA CARBIDOPA ANDDESIPRAMINE IN HEALTHY-VOLUNTEERS/
Authors: JORGA K FOTTELER B SEDEK G MODI M RABBIA M
Citation: K. Jorga et al., EFFECT OF THE COMT INHIBITOR TOLCAPONE ON THE HEMODYNAMIC-EFFECTS ANDTOLERABILITY OF THE COMBINATION TREATMENT WITH LEVODOPA CARBIDOPA ANDDESIPRAMINE IN HEALTHY-VOLUNTEERS/, Neurology, 48(3), 1997, pp. 3103-3103
THE EFFECT OF COMT INHIBITION BY TOLCAPONE ON TOLERABILITY AND PHARMACOKINETICS OF DIFFERENT LEVODOPA BENSERAZIDE FORMULATIONS/
Authors: JORGA K FOTTELER B SCHMITT M NIELSEN T ZURCHER G AITKEN J
Citation: K. Jorga et al., THE EFFECT OF COMT INHIBITION BY TOLCAPONE ON TOLERABILITY AND PHARMACOKINETICS OF DIFFERENT LEVODOPA BENSERAZIDE FORMULATIONS/, European neurology, 38(1), 1997, pp. 59-67
OPTIMIZING LEVODOPA PHARMACOKINETICS WITH MULTIPLE TOLCAPONE DOSES INTHE ELDERLY
Authors: JORGA KM SEDEK G FOTTELER B ZURCHER G NIELSEN T AITKEN JW
Citation: Km. Jorga et al., OPTIMIZING LEVODOPA PHARMACOKINETICS WITH MULTIPLE TOLCAPONE DOSES INTHE ELDERLY, Clinical pharmacology and therapeutics, 62(3), 1997, pp. 300-310
WHY SHOULD TOLCAPONE BE GIVEN AT A LOWER DOSE TO PATIENTS WITH LIVER-CIRRHOSIS
Authors: JORGA K FOTTELER B VANBRUMMELEN P
Citation: K. Jorga et al., WHY SHOULD TOLCAPONE BE GIVEN AT A LOWER DOSE TO PATIENTS WITH LIVER-CIRRHOSIS, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 73-73
MULTIPLE-DOSE CLINICAL-PHARMACOLOGY OF THE CATECHOL-O-METHYL-TRANSFERASE INHIBITOR TOLCAPONE IN ELDERLY SUBJECTS
Authors: DINGEMANSE J JORGA K ZURCHER G FOTTELER B SEDEK G NIELSEN T VANBRUMMELEN P
Citation: J. Dingemanse et al., MULTIPLE-DOSE CLINICAL-PHARMACOLOGY OF THE CATECHOL-O-METHYL-TRANSFERASE INHIBITOR TOLCAPONE IN ELDERLY SUBJECTS, European Journal of Clinical Pharmacology, 50(1-2), 1996, pp. 47-55
SWITCH IN TREATMENT FROM TRICYCLIC ANTIDEPRESSANTS TO MOCLOBEMIDE - ANEW-GENERATION MONOAMINE-OXIDASE INHIBITOR
Authors: DINGEMANSE J KNEER J FOTTELER B GROEN H PEETERS PAM JONKMAN JHG
Citation: J. Dingemanse et al., SWITCH IN TREATMENT FROM TRICYCLIC ANTIDEPRESSANTS TO MOCLOBEMIDE - ANEW-GENERATION MONOAMINE-OXIDASE INHIBITOR, Journal of clinical psychopharmacology, 15(1), 1995, pp. 41-48
INTEGRATED PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NOVEL CATECHOL-O-METHYLTRANSFERASE INHIBITOR TOLCAPONE DURING FIRST ADMINISTRATION TO HUMANS
Authors: DINGEMANSE J JORGA KM SCHMITT M GIESCHKE R FOTTELER B ZURCHER G DAPRADA M VANBRUMMELEN P
Citation: J. Dingemanse et al., INTEGRATED PHARMACOKINETICS AND PHARMACODYNAMICS OF THE NOVEL CATECHOL-O-METHYLTRANSFERASE INHIBITOR TOLCAPONE DURING FIRST ADMINISTRATION TO HUMANS, Clinical pharmacology and therapeutics, 57(5), 1995, pp. 508-517
Risultati: 1-10 |